Back to Search Start Over

Clinical implementation of RNA sequencing for Mendelian disease diagnostics

Authors :
Vicente A. Yépez
Mirjana Gusic
Robert Kopajtich
Christian Mertes
Nicholas H. Smith
Charlotte L. Alston
Rui Ban
Skadi Beblo
Riccardo Berutti
Holger Blessing
Elżbieta Ciara
Felix Distelmaier
Peter Freisinger
Johannes Häberle
Susan J. Hayflick
Maja Hempel
Yulia S. Itkis
Yoshihito Kishita
Thomas Klopstock
Tatiana D. Krylova
Costanza Lamperti
Dominic Lenz
Christine Makowski
Signe Mosegaard
Michaela F. Müller
Gerard Muñoz-Pujol
Agnieszka Nadel
Akira Ohtake
Yasushi Okazaki
Elena Procopio
Thomas Schwarzmayr
Joél Smet
Christian Staufner
Sarah L. Stenton
Tim M. Strom
Caterina Terrile
Frederic Tort
Rudy Van Coster
Arnaud Vanlander
Matias Wagner
Manting Xu
Fang Fang
Daniele Ghezzi
Johannes A. Mayr
Dorota Piekutowska-Abramczuk
Antonia Ribes
Agnès Rötig
Robert W. Taylor
Saskia B. Wortmann
Kei Murayama
Thomas Meitinger
Julien Gagneur
Holger Prokisch
Source :
Genome Medicine, Vol 14, Iss 1, Pp 1-26 (2022)
Publication Year :
2022
Publisher :
BMC, 2022.

Abstract

Abstract Background Lack of functional evidence hampers variant interpretation, leaving a large proportion of individuals with a suspected Mendelian disorder without genetic diagnosis after whole genome or whole exome sequencing (WES). Research studies advocate to further sequence transcriptomes to directly and systematically probe gene expression defects. However, collection of additional biopsies and establishment of lab workflows, analytical pipelines, and defined concepts in clinical interpretation of aberrant gene expression are still needed for adopting RNA sequencing (RNA-seq) in routine diagnostics. Methods We implemented an automated RNA-seq protocol and a computational workflow with which we analyzed skin fibroblasts of 303 individuals with a suspected mitochondrial disease that previously underwent WES. We also assessed through simulations how aberrant expression and mono-allelic expression tests depend on RNA-seq coverage. Results We detected on average 12,500 genes per sample including around 60% of all disease genes—a coverage substantially higher than with whole blood, supporting the use of skin biopsies. We prioritized genes demonstrating aberrant expression, aberrant splicing, or mono-allelic expression. The pipeline required less than 1 week from sample preparation to result reporting and provided a median of eight disease-associated genes per patient for inspection. A genetic diagnosis was established for 16% of the 205 WES-inconclusive cases. Detection of aberrant expression was a major contributor to diagnosis including instances of 50% reduction, which, together with mono-allelic expression, allowed for the diagnosis of dominant disorders caused by haploinsufficiency. Moreover, calling aberrant splicing and variants from RNA-seq data enabled detecting and validating splice-disrupting variants, of which the majority fell outside WES-covered regions. Conclusion Together, these results show that streamlined experimental and computational processes can accelerate the implementation of RNA-seq in routine diagnostics.

Details

Language :
English
ISSN :
1756994X
Volume :
14
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Genome Medicine
Publication Type :
Academic Journal
Accession number :
edsdoj.84ca93f6ba94f7fa60fa360f03b6d83
Document Type :
article
Full Text :
https://doi.org/10.1186/s13073-022-01019-9